JAK
Janus kinases (JAKs), belonging to a distinct family of tyrosine kinases, are non-receptor tyrosine kinases that transduce signals of cytokine receptors via diverse signal transduction pathways. Mammalian JAK family consists of four structurally similar members, JAK1, JAK2, JAK3 and Tyrosine kinase 2 (TYK2), which are characterized by containing seven JAK homology (JH) domains. The presence of JH1 and JH2 domains is the most intriguing feature of JAK proteins. JH1 domain is the main catalytic domain; while JH2 is usually considered as a catalytically inactive pseudokinase domain. However, results of recent studies have shown that JH2 acts as a dual-specificity protein kinase to phosphorylate two regulatory sites (Ser523 and Tyr570) in JAK2.
- Cat.No. Product Name Information
-
A4510
1,2,3,4,5,6-Hexabromocyclohexane
JAK2 tyrosine kinase inhibitor
-
A4144
AZ 960
JAKs inhibitor
-
A4137
AZD1480
JAK2 inhibitor,ATP-competitive and novel
-
A3221
Bardoxolone methyl
IKK inhibitor, potent antioxidant inflammation modulator
-
A4141
Baricitinib (LY3009104, INCB028050)
JAK1/JAK2 inhibitor,selective orally bioavailable
-
A3222
Baricitinib phosphate
JAK1/JAK2 inhibitor
-
A4152
BMS-911543
JAK2 inhibitor,selective small molecule
-
A4146
CEP-33779
JAK2 inhibitor,highly selective
-
A4511
Cercosporamide
Mnk2 and JAK3 inhibitor
-
A4512
Cucurbitacin I
STAT3/JAK2 signaling inhibitor